Results 261 to 270 of about 79,270 (300)
Some of the next articles are maybe not open access.
Nonurologic applications of phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2007Phosphodiesterase type 5 (PDE5) is an enzyme that catalyzes hydrolytic degradation of cyclic guanosine monophosphate, an essential intracellular second messenger that modulates diverse biologic processes in living cells. Three selective inhibitors of PDE5, sildenafil, vardenafil, and tadalafil, have been successfully used by millions of people ...
Rakesh C. Kukreja +2 more
openaire +1 more source
Type 5 Phosphodiesterase Inhibitors: Curing Erectile Dysfunction
European Urology, 2006Basic science research on erectile physiology has focused on the pathogenesis of erectile dysfunction (ED) and has provided convincing evidence that ED is predominately a disease of vascular etiology correlating with coronary artery disease, hypertension, atherosclerosis, hyperlipidemia, smoking, and diabetes mellitus [1,2].
Wayne J.G. Hellstrom, Muammer Kendirci
openaire +1 more source
Phosphodiesterase type 5 inhibitors and endothelial function
Current Sexual Health Reports, 2007Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage.
Antonio Aversa, Roberto Bruzziches
openaire +1 more source
Current Pharmaceutical Design, 2005
Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular events in the penile smooth muscle ...
openaire +2 more sources
Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular events in the penile smooth muscle ...
openaire +2 more sources
FR226807: a potent and selective phosphodiesterase type 5 inhibitor
European Journal of Pharmacology, 2001We describe the pharmacological characteristics of a novel phosphodiesterase type 5 inhibitor FR226807, N-(3,4-dimethoxybenzyl)-2-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-nitrobenzamide. FR226807 inhibited phosphodiesterase type 5 isolated from human platelets with an IC(50) value of 1.1 nM. FR226807 also inhibited phosphodiesterase type 6 with an IC(50)
N, Hosogai +12 more
openaire +2 more sources
Chronic dosing of phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2008Ten years ago, the introduction of sildenafil citrate for the treatment of erectile dysfunction fundamentally changed the field of sexual medicine. The sexual indications, along with the pharmacologic characteristics of this drug, led to its approval for on-demand use.
openaire +1 more source
Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon
Rheumatology International, 2014Raynaud's phenomenon (RP) is commonly observed in fingers and toes of patients with connective tissue diseases (CTDs). However, existing vasodilators have very limited efficacy. In this study, phosphodiesterase type 5 inhibitors (PDE-5Is) were administered to evaluate efficacy on RP.
Yasuyuki, Kamata, Seiji, Minota
openaire +2 more sources
Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors
Vascular, 2013Thromboangiitis obliterans, or Buerger’s disease, is a non-atherosclerotic, segmental, inflammatory disease affecting the small- and medium-sized vessels of the distal extremities. Other than discontinuation of tobacco, there is no standard-of-care treatment.
Aryeh M, Abeles +3 more
openaire +2 more sources
Optimizing response to phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2007Although using phosphodiesterase type 5 inhibitors to treat erectile dysfunction has been highly effective in clinical trials, many men do not achieve their desired goals and stop using the medication after a few attempts. The notion of optimizing response to pharmacologic interventions is relatively new to clinicians.
openaire +1 more source
[Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Revue medicale de Bruxelles, 2003Erectile dysfunction affects 150 millions of men and its prevalence increases with age. The improvement of life expectancy will increase the worldwide prevalence to 300 million in 2025. Oral treatments are nowadays the first line therapy for the vast majority of people as they have a good reliability and tolerance and restore more spontaneity.
T, Roumeguère +2 more
openaire +1 more source